Cargando…

A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction

PURPOSE: A model for predicting the prognosis of patients with heart failure with reduced left ventricular ejection fraction (HFrEF) is currently not available. This study aimed to develop an age-biomarker-clinical history prognostic index (ABC-PI) and validate it for the assessment of individual pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hao, Cui, Yuan, Tian, Jin, Yang, Hong, Zhang, Qing, Wang, Ke, Han, Qinghua, Zhang, Yanbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712124/
https://www.ncbi.nlm.nih.gov/pubmed/33336021
http://dx.doi.org/10.1515/med-2020-0209
_version_ 1783618300995960832
author Li, Hao
Cui, Yuan
Tian, Jin
Yang, Hong
Zhang, Qing
Wang, Ke
Han, Qinghua
Zhang, Yanbo
author_facet Li, Hao
Cui, Yuan
Tian, Jin
Yang, Hong
Zhang, Qing
Wang, Ke
Han, Qinghua
Zhang, Yanbo
author_sort Li, Hao
collection PubMed
description PURPOSE: A model for predicting the prognosis of patients with heart failure with reduced left ventricular ejection fraction (HFrEF) is currently not available. This study aimed to develop an age-biomarker-clinical history prognostic index (ABC-PI) and validate it for the assessment of individual prognosis. PATIENTS AND METHODS: A total of 5,974 HFrEF patients were enrolled and 1,529 were included in this study after excluding missing values and loss to follow-up. Variables that significantly contributed to prediction of all-cause mortality were assessed by Cox regression and latent trait analysis (LTA) was used to validate discrimination of variables. RESULTS: After Cox regression, the following seven most significant variables were selected: age, N-terminal pro-B-type natriuretic peptide, renal dysfunction, left ventricular mass index, percutaneous coronary intervention, atrial fibrillation, and New York Heart Association (C-index: 0.801 ± 0.013). After verification by LTA, discrimination of these seven variables was proven. A nomogram was used to form the ABC-PI, and then the total score was set to 100 points. A lower score indicated a higher risk. After verification, the 3-year mortality rate was 34.7% in the high-risk group and only 2.6% in the low-risk group. CONCLUSION: Our novel ABC-PI shows a good performance and does not require re-input in the original model. The ABC-PI can be used to effectively and practically predict the prognosis of HFrEF patients.
format Online
Article
Text
id pubmed-7712124
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-77121242020-12-16 A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction Li, Hao Cui, Yuan Tian, Jin Yang, Hong Zhang, Qing Wang, Ke Han, Qinghua Zhang, Yanbo Open Med (Wars) Research Article PURPOSE: A model for predicting the prognosis of patients with heart failure with reduced left ventricular ejection fraction (HFrEF) is currently not available. This study aimed to develop an age-biomarker-clinical history prognostic index (ABC-PI) and validate it for the assessment of individual prognosis. PATIENTS AND METHODS: A total of 5,974 HFrEF patients were enrolled and 1,529 were included in this study after excluding missing values and loss to follow-up. Variables that significantly contributed to prediction of all-cause mortality were assessed by Cox regression and latent trait analysis (LTA) was used to validate discrimination of variables. RESULTS: After Cox regression, the following seven most significant variables were selected: age, N-terminal pro-B-type natriuretic peptide, renal dysfunction, left ventricular mass index, percutaneous coronary intervention, atrial fibrillation, and New York Heart Association (C-index: 0.801 ± 0.013). After verification by LTA, discrimination of these seven variables was proven. A nomogram was used to form the ABC-PI, and then the total score was set to 100 points. A lower score indicated a higher risk. After verification, the 3-year mortality rate was 34.7% in the high-risk group and only 2.6% in the low-risk group. CONCLUSION: Our novel ABC-PI shows a good performance and does not require re-input in the original model. The ABC-PI can be used to effectively and practically predict the prognosis of HFrEF patients. De Gruyter 2020-07-10 /pmc/articles/PMC7712124/ /pubmed/33336021 http://dx.doi.org/10.1515/med-2020-0209 Text en © 2020 Hao Li et al., published by De Gruyter http://creativecommons.org/licenses/by/4.0 This work is licensed under the Creative Commons Attribution 4.0 International License.
spellingShingle Research Article
Li, Hao
Cui, Yuan
Tian, Jin
Yang, Hong
Zhang, Qing
Wang, Ke
Han, Qinghua
Zhang, Yanbo
A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction
title A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction
title_full A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction
title_fullStr A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction
title_full_unstemmed A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction
title_short A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction
title_sort novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712124/
https://www.ncbi.nlm.nih.gov/pubmed/33336021
http://dx.doi.org/10.1515/med-2020-0209
work_keys_str_mv AT lihao anovelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction
AT cuiyuan anovelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction
AT tianjin anovelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction
AT yanghong anovelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction
AT zhangqing anovelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction
AT wangke anovelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction
AT hanqinghua anovelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction
AT zhangyanbo anovelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction
AT lihao novelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction
AT cuiyuan novelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction
AT tianjin novelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction
AT yanghong novelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction
AT zhangqing novelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction
AT wangke novelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction
AT hanqinghua novelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction
AT zhangyanbo novelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction